Zobrazeno 1 - 10
of 222
pro vyhledávání: '"Gary L Davis"'
Autor:
Jacqueline G. O'Leary, Gary L. Davis
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 3 (2010)
We finally stand at the brink of novel, oral, direct-acting antivirals for the treatment of hepatitis C virus (HCV) infection. Basic science research has lead to a greater understanding of the viral life cycle and identified numerous potential target
Externí odkaz:
https://doaj.org/article/8a89af8f912f4bf69e9cc1ac09499029
Autor:
Arnold G. Levy, Stuart C. Gordon, Ronald Nahass, Lawrence R. Kosinski, John I. Allen, Mark D. Boldt, Joel V. Brill, Arthur Y. Kim, Gary L. Davis
Publikováno v:
Gastroenterology. 145:1146-1149
The Hepatitis C Task Force includes: Mark D. Boldt, RN, CNP, Minnesota Gastroenterology; Joel V. Brill, MD, AGAF, Predictive Health; Gary L. Davis, MD, Baylor University Medical Center Dallas(retired); Stuart C. Gordon, MD, AGAF, Henry Ford Health Sy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faaf9ec8091583106f177e615ddf04ab
https://doi.org/10.1053/j.gastro.2013.09.007
https://doi.org/10.1053/j.gastro.2013.09.007
Autor:
Peter T. W. Kim, Marlon F. Levy, Linda W. Jennings, Nicholas Onaca, Robert M. Goldstein, Goran B. Klintmalm, Greg J. McKenna, Gary L. Davis, Richard Ruiz, Srinath Chinnakotla
Publikováno v:
Clinical Transplantation. 27:311-318
Liver transplantation is the optimal treatment for patients with hepatocellular carcinoma (HCC) and cirrhosis. This study was conducted to determine the impact of pre-transplant locoregional therapy (LRT) on HCC and our institution's experience with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7493c75cd0cf909b835bd109c47e0613
https://doi.org/10.1111/ctr.12089
https://doi.org/10.1111/ctr.12089
Autor:
James F. Trotter, Jane Dempster, John K. O'Connor, Gary L. Davis, Goran B. Klintmalm, Robert M. Goldstein
Publikováno v:
Liver Transplantation. 18:949-954
Hepatocellular carcinoma (HCC) is potentially curable with hepatic resection or transplantation. Few patients are eligible for resection, and many face a long wait for donor organ availability for liver transplantation. Here we report the safety and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80f62e4526436137a3f8663620fd6421
https://doi.org/10.1002/lt.23439
https://doi.org/10.1002/lt.23439
Publikováno v:
Transplant International. 25:825-829
Because of the unrelenting donor shortage, utilization of all potential liver donors is essential. However, when utilizing marginal donors it is critical to precisely characterize the risks, inform recipients of those risks, and allocate these higher
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3868a71ce44ed3698a11825b9bbf25a
https://doi.org/10.1111/j.1432-2277.2012.01498.x
https://doi.org/10.1111/j.1432-2277.2012.01498.x
Autor:
James F. Trotter, Jacqueline G. O'Leary, M. F. Levy, Linda W. Jennings, Michael A. Neri, Nicholas Onaca, Richard Ruiz, Goran B. Klintmalm, E. Klintmalm, Gary L. Davis, Greg J. McKenna, Robert M. Goldstein
Publikováno v:
American Journal of Transplantation. 11:2379-2387
Hepatitis C virus (HCV) causes progressive liver fibrosis in liver transplant recipients and is the principal cause of long-term allograft failure. The antifibrotic effects of sirolimus are seen in animal models but have not been described in liver t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb9ba6ff35d407fd5eb3cb545dbf4438
https://doi.org/10.1111/j.1600-6143.2011.03767.x
https://doi.org/10.1111/j.1600-6143.2011.03767.x
Autor:
Srinath Chinnakotla, Greg J. McKenna, Peter T. W. Kim, Goran B. Klintmalm, Linda W. Jennings, Richard Ruiz, Nicholas Onaca, Gary L. Davis, Robert H. Goldstein, Marlon F. Levy
Publikováno v:
Baylor University Medical Center Proceedings. 24:287-294
Different renal-sparing immunosuppressive protocols have been used in liver transplantation. At our institution, muromonab-CD3 (OKT3) is used in patients with acute renal failure (ARF), along with a delay in starting a calcineurin inhibitor. This stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce78b6b1f6670764b51af44fcf6cf0d1
https://doi.org/10.1080/08998280.2011.11928740
https://doi.org/10.1080/08998280.2011.11928740
Autor:
Gary L. Davis
Publikováno v:
Clinical Liver Disease. 3:93-95
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::217d872f5d5c6bbbdc08c8e9aea07bb4
https://doi.org/10.1002/cld.348
https://doi.org/10.1002/cld.348
Publikováno v:
Clinical Gastroenterology and Hepatology. 8:924-933
Hepatitis C virus (HCV) infections pose a growing challenge to health care systems. Although chronic HCV infection begins as an asymptomatic condition with few short-term effects, it can progress to cirrhosis, hepatic decompensation, hepatocellular c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccb3851a416a026374fc752fa530ba23
https://doi.org/10.1016/j.cgh.2010.06.032
https://doi.org/10.1016/j.cgh.2010.06.032
Publikováno v:
Liver Transplantation. 16:431-439
Nonalcoholic steatohepatitis (NASH) may account for many cases of cryptogenic cirrhosis. If so, then steatosis might recur after liver transplantation. Two thousand fifty-two patients underwent primary liver transplantation for chronic liver disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c3d51788e149db908aa4130dfcd6228
https://doi.org/10.1002/lt.22004
https://doi.org/10.1002/lt.22004